These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 25661711)

  • 21. A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species.
    Excoffier M; Janin-Bussat MC; Beau-Larvor C; Troncy L; Corvaia N; Beck A; Klinguer-Hamour C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():149-154. PubMed ID: 27267073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current methods for the synthesis of homogeneous antibody-drug conjugates.
    Sochaj AM; Świderska KW; Otlewski J
    Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of Human Pharmacokinetics of Antibody-Drug Conjugates From Nonclinical Data.
    Li C; Zhang C; Deng R; Leipold D; Li D; Latifi B; Gao Y; Zhang C; Li Z; Miles D; Chen SC; Samineni D; Wang B; Agarwal P; Lu D; Prabhu S; Girish S; Kamath AV
    Clin Transl Sci; 2019 Sep; 12(5):534-544. PubMed ID: 31115997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.
    Chia CSB
    ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody Drug Conjugates: Preclinical Considerations.
    Bornstein GG
    AAPS J; 2015 May; 17(3):525-34. PubMed ID: 25724883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A brief survey of first-in-human studies.
    Wexler D; Bertelsen KM
    J Clin Pharmacol; 2011 Jul; 51(7):988-93. PubMed ID: 20671293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.
    Lu D; Jin JY; Girish S; Agarwal P; Li D; Prabhu S; Dere RC; Saad OM; Nazzal D; Koppada N; Ramanujan S; Ng CM
    Pharm Res; 2015 Jun; 32(6):1907-19. PubMed ID: 25467958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
    Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
    Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
    Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
    MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody Drug Conjugates for Cancer Therapy.
    Polakis P
    Pharmacol Rev; 2016 Jan; 68(1):3-19. PubMed ID: 26589413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.
    Poon KA; Flagella K; Beyer J; Tibbitts J; Kaur S; Saad O; Yi JH; Girish S; Dybdal N; Reynolds T
    Toxicol Appl Pharmacol; 2013 Dec; 273(2):298-313. PubMed ID: 24035823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.
    Hinrichs MJM; Ryan PM; Zheng B; Afif-Rider S; Yu XQ; Gunsior M; Zhong H; Harper J; Bezabeh B; Vashisht K; Rebelatto M; Reed M; Ryan PC; Breen S; Patel N; Chen C; Masterson L; Tiberghien A; Howard PW; Dimasi N; Dixit R
    Clin Cancer Res; 2017 Oct; 23(19):5858-5868. PubMed ID: 28630216
    [No Abstract]   [Full Text] [Related]  

  • 35. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of the relationship between a starting dose in first-in-human studies and no observed adverse effect level in nonclinical studies.
    Sato A; Narukawa M
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):770-6. PubMed ID: 25034619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicologic Pathology Forum: Opinion on Approaches for Reporting Toxic and Adverse Dose Levels in Nonclinical Toxicology Studies Supporting the Development of Anticancer Pharmaceuticals.
    Hukkanen RR; Moriyama T; Patrick DJ; Werner J
    Toxicol Pathol; 2023 Jan; 51(1-2):81-86. PubMed ID: 36695335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.
    Nilsson R; Eriksson SE; Sjögren HO; Tennvall J
    Acta Oncol; 2011 Jun; 50(5):711-8. PubMed ID: 21214493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.
    Sauerborn M; van Dongen W
    BioDrugs; 2014 Aug; 28(4):383-91. PubMed ID: 24842227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials.
    Kornbrust D
    Nucleic Acid Ther; 2019 Jun; 29(3):123-125. PubMed ID: 30817231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.